About Adicet Bio
Adicet Bio is a company based in Menlo Park (United States) founded in 2014. Adicet Bio has raised $51 million across 5 funding rounds from investors including Regeneron Pharmaceuticals, HHS and Handok. The company has 152 employees as of December 31, 2024. Adicet Bio has completed 1 acquisition, including Applied Immune Technologies. Adicet Bio operates in a competitive market with competitors including Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others.
- Headquarter Menlo Park, United States
- Employees 152 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Adicet Bio, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$117.12 M (USD)17.9as on Dec 31, 2024
-
EBITDA
-$121.15 M (USD)4.21as on Dec 31, 2024
-
Total Equity Funding
$51 M (USD)
in 5 rounds
-
Latest Funding Round
$15 M (USD), Post-IPO
Feb 16, 2021
-
Investors
Regeneron Pharmaceuticals
& 13 more
-
Employee Count
152
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Adicet Bio
Adicet Bio is a publicly listed company on the NASDAQ with ticker symbol ACET in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Adicet Bio
Unlock access to complete
Unlock access to complete
Leadership Team
23 people
Software Development Team
9 people
Senior Team
8 people
Scientific Team
6 people
Scientist Team
5 people
Product Management Team
4 people
Human Resources and Administration
4 people
Finance and Accounting
3 people
Unlock access to complete
Funding Insights of Adicet Bio
Adicet Bio has successfully raised a total of $51M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Adicet Bio
Adicet Bio has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Regeneron Pharmaceuticals, HHS and Handok.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in healthcare are focused on by aMoon.
|
Locked | Locked | Locked | |
|
Venture capital investments are made in promising startups.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked |
Investor details for Adicet Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Adicet Bio
Adicet Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Applied Immune Technologies.
Investment portfolio details for Adicet Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
TCRL antibodies are developed for therapeutic and diagnostic applications.
|
Locked | Locked | 2006 | Locked |
Complete acquisition details for Adicet Bio
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Adicet Bio
Detailed financials for Adicet Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Adicet Bio Comparisons
Peer comparison for Adicet Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Adicet Bio
Adicet Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| Locked | Locked | Locked |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.
|
|
| Locked | Locked | Locked |
Developer of CAAR T cells for B cell-mediated autoimmune diseases
|
Detailed competitors of Adicet Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Adicet Bio
Complete news archive for Adicet Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adicet Bio
Adicet Bio was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Adicet Bio is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Anil Singhal is the current CEO of Adicet Bio.
Adicet Bio is a funded company, having raised a total of $51M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Adicet Bio is 152.
Adicet Bio was founded in 2014 and is headquartered in Menlo Park, United States. Operations focus on biotechnology, with immune cell therapeutic solutions developed for cancer and immune diseases. Universal immune cell therapies remain in pre-clinical stages, including ADI-001 targeting CD20 for lymphoma, ADI-002 targeting GPC3, and ADI-00x for solid tumors. Leadership is provided by CEO Anil Singhal.
Adicet Bio's top competitors include Juno Therapeutics, Lyell Immunopharma and Immatics.
Yes, Adicet Bio is publicly traded on NASDAQ under the ticker symbol ACET.
Adicet Bio has made 1 acquisition, including Applied Immune Technologies.
Adicet Bio has 14 investors. Key investors include Regeneron Pharmaceuticals, HHS, Handok, Orbimed, and Samsung Venture Investment.
The ticker symbol of Adicet Bio is ACET on NASDAQ.